학술논문
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, January 2019, 20(1):43-56)
Subject
Language
English
ISSN
14745488
14702045
14702045